Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects With Atopic Dermatitis

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms KARE
  • Sponsors Cara Therapeutics

    • Most Recent Events

    • 13 Jul 2023 Results assessing the impact of the selective kappa-opioid receptor agonist difelikefalin (DFK) on pruritus intensity and pruritus- and immune-related biomarkers in subjects with moderate-to-severe AD-related pruritus published in the Journal of Allergy and Clinical Immunology
    • 28 Mar 2022 According to a Cara Therapeutics media release, Emma Guttman-Yassky is the lead investigator
    • 28 Mar 2022 According to a Cara Therapeutics media release, The biomarker data were presented during the Late-Breaking Research: Clinical Trials session at the 2022 American Academy of Dermatology (AAD) Annual Meeting.In addition to the late-breaking oral presentation, quality of life data from a subgroup analysis of the KARE trial were presented in a poster at the 2022 AAD Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top